FY2030 Earnings Forecast for ARWR Issued By B. Riley

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Analysts at B. Riley issued their FY2030 earnings estimates for shares of Arrowhead Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 25th. B. Riley analyst M. El-Saadi expects that the biotechnology company will post earnings per share of $6.48 for the year. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share.

Several other brokerages also recently weighed in on ARWR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. Morgan Stanley upped their price objective on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Chardan Capital reiterated a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, November 19th. HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. Finally, Piper Sandler increased their price objective on shares of Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Arrowhead Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $51.63.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ ARWR opened at $52.78 on Thursday. The stock has a market cap of $7.30 billion, a PE ratio of -41.23 and a beta of 1.27. Arrowhead Pharmaceuticals has a 1 year low of $9.57 and a 1 year high of $59.15. The firm has a fifty day moving average price of $39.14 and a 200-day moving average price of $25.90. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several large investors have recently bought and sold shares of ARWR. CIBC Bancorp USA Inc. purchased a new stake in Arrowhead Pharmaceuticals during the third quarter valued at $444,000. Keystone Financial Group purchased a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at about $276,000. CANADA LIFE ASSURANCE Co raised its position in shares of Arrowhead Pharmaceuticals by 11.7% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 129,958 shares of the biotechnology company’s stock valued at $4,389,000 after buying an additional 13,653 shares in the last quarter. Woodline Partners LP grew its position in Arrowhead Pharmaceuticals by 34.0% in the third quarter. Woodline Partners LP now owns 1,000,158 shares of the biotechnology company’s stock worth $34,495,000 after acquiring an additional 254,002 shares in the last quarter. Finally, Virtus Advisers LLC increased its stake in Arrowhead Pharmaceuticals by 581.5% during the third quarter. Virtus Advisers LLC now owns 14,462 shares of the biotechnology company’s stock worth $499,000 after acquiring an additional 12,340 shares during the last quarter. Institutional investors own 62.61% of the company’s stock.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. Following the sale, the insider directly owned 212,122 shares of the company’s stock, valued at $7,424,270. This represents a 8.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders sold 50,000 shares of company stock valued at $1,525,000. Insiders own 4.30% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.